BioWorld

Feb. 15, 2010

View Archived Issues

Safety Brouhaha Tests 'Mettle' of Feraheme After Downgrade

Alexza Just See: Biovail Deal Spotlights AZ-004's Way Forth

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

FDA Approvals In January

Phase I Clinical Trials Update: January 2010

Phase II Clinical Trials Update: January 2010

Pivotal/Phase III Clinical Trials Update: February 2010

Non-U.S. Clinical Trials And Regulatory Actions: February 2010

Celera's Hidden Treasure: A 'Royal' Road to Payoff?

Last week, the Biotechnology Value Fund (BVF) proposed that Celera Corp. separate its low margin diagnostics business from its potentially high-margin drug royalty stream. Read More

Money Raised Year to Date

FDA Submissions, Approvals And Other Actions: February 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...

Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent

BioWorld Science

Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...